Literature DB >> 15607571

Unifying mechanism for toxicity and addiction by abused drugs: electron transfer and reactive oxygen species.

Peter Kovacic1, Andrew L Cooksy.   

Abstract

Abused drugs are of grave concern throughout the world for a variety of reasons. Although impressive advances have been made, there are many unknown mechanistic aspects. This report presents a novel hypothesis based on a unifying theme for action of the major classes of abused drugs, in addition to commonly abused therapeutic drugs. The approach is based on electron transfer (ET), reactive oxygen species (ROS), and oxidative stress (OS). It is significant that physiologically active substances generally incorporate ET functionalities, either per se, or more usually in their metabolites. In order to achieve ET in vivo, the reduction potential must be more positive than -0.5 V, which is the case for metabolites of abused drugs, except for special cases. Since the ET process is catalytic, only small quantities of agent are needed for generation of large amounts of ROS during redox cycyling. Bioaction with cellular materials could entail ET alone or participation of ROS. In the abused category, among the main classes of ET functionalities are quinones and iminiums, with alpha-dicarbonyl and nitroxyl radical being rarer. Nicotine yields nicotine iminium, myosmine iminium, and DNA base iminium via alkylation by a metabolic nitrosamine. In the case of alcohol, diacetyl (an alpha-dicarbonyl) is formed, which can lead to conjugated imine (or iminium) by condensation with pri-amine of protein. Phencyclidine is unusual since the iminium product is non-conjugated. However, data indicate that the conformation present at the binding site can accommodate delocalization of the derived radical. For cocaine, various metabolites may play a role: iminium, nitroxyl radical, nitrosonium and formaldehyde. Dealkylation of the ether moiety of ecstasy provides a catechol function capable of redox cycling with the o-quinone partner. Amphetamine and methamphetamine also appear to function by way of the catechol route, as well as morphine and heroin. Tetrahydrocannabinol produces an epoxide, a functionality capable of DNA base alkylation accompanied by ROS. LSD undergoes oxidation to a phenol which may be a quinone precursor. Therapeutic drugs display the indicated metabolic relationships: benzodiazepines, iminium; phenytoin, quinone; phenobarbital, catechol; aspirin, catechol and hydroquinone; acetaminophen, iminoquinone. Extensive evidence exists for formation of ROS, organ injury by OS, depletion of AOs, and protection by AOs for the various drugs. There is also discussion of computational approaches, addiction mechanism and prevention, and health promotion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607571     DOI: 10.1016/j.mehy.2004.07.021

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  14 in total

1.  Increased cocaine and amphetamine-regulated transcript cord blood levels in the newborns exposed to crack cocaine in utero.

Authors:  Rodrigo Ritter Parcianello; Victor Mardini; Keila Maria Mendes Ceresér; Daniel D Langleben; Fernando Xavier; Maria Lucrécia Scherer Zavaschi; Luis Augusto Paim Rhode; Flávio Pechansky; Carolina Gubert; Claudia Maciel Szobot
Journal:  Psychopharmacology (Berl)       Date:  2017-10-28       Impact factor: 4.530

2.  Oxidative stress and BDNF as possible markers for the severity of crack cocaine use in early withdrawal.

Authors:  Anne Orgle Sordi; Flavio Pechansky; Felix Henrique Paim Kessler; Flávio Kapczinski; Bianca Pfaffenseller; Carolina Gubert; Bianca Wollenhaupt de Aguiar; Joana Correa de Magalhães Narvaez; Felipe Ornell; Lisia von Diemen
Journal:  Psychopharmacology (Berl)       Date:  2014-03-28       Impact factor: 4.530

3.  Novel, unifying mechanism for mescaline in the central nervous system: electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2009 Sep-Oct       Impact factor: 6.543

Review 4.  Clinical physiology and mechanism of dizocilpine (MK-801): electron transfer, radicals, redox metabolites and bioactivity.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2010 Jan-Feb       Impact factor: 6.543

Review 5.  Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

6.  Immunohistochemical increase in cyclooxygenase-2 without apoptosis in different brain areas of subchronic nicotine- and D-amphetamine-treated rats.

Authors:  A Toledano; M I Alvarez; I Caballero; P Carmona; E De Miguel
Journal:  J Neural Transm (Vienna)       Date:  2008-03-20       Impact factor: 3.575

Review 7.  Live-cell imaging approaches for the investigation of xenobiotic-induced oxidant stress.

Authors:  Phillip A Wages; Wan-Yun Cheng; Eugene Gibbs-Flournoy; James M Samet
Journal:  Biochim Biophys Acta       Date:  2016-05-18

8.  Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4.

Authors:  X Wang; Y Zhang; Y Peng; M R Hutchinson; K C Rice; H Yin; L R Watkins
Journal:  Br J Pharmacol       Date:  2016-02-04       Impact factor: 8.739

9.  Convergence of genetic influences in comorbidity.

Authors:  Richard C McEachin; Keerthi S Sannareddy; James D Cavalcoli; Alla Karnovsky; Jacqueline M Vink; Maureen A Sartor
Journal:  BMC Bioinformatics       Date:  2012-03-13       Impact factor: 3.169

Review 10.  Zolpidem, a clinical hypnotic that affects electronic transfer, alters synaptic activity through potential GABA receptors in the nervous system without significant free radical generation.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2009 Jan-Mar       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.